BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 06, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Dolorac Nasal Solution: Phase II data

Top-line data from a double-blind Phase II trial in 92 evaluable patients with >=180 headache days per year showed that twice-daily Dolorac for either 14 or 28 days missed the primary endpoint of significantly reducing headache frequency vs. vehicle (44% vs. 41% reductions, p=0.3338). The endpoint was measured from treatment period 1, in which patients received single-blinded twice-daily vehicle for 28...

Read the full 284 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >